Where is Caldera Therapeutics located?

Caldera Therapeutics is headquartered in San Francisco, United States.

Is Caldera Therapeutics a funded company?

Caldera Therapeutics is a funded company, having raised a total of $112M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 2025.

When was the latest funding round of Caldera Therapeutics?

Caldera Therapeutics' latest funding was a $***** Series A round on Jan 08, 2026, with participation from 3 investors.

Where does Caldera Therapeutics rank among its competitors?

Caldera Therapeutics ranks 24th amongst 58 active competitors, of which 25 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was MRM Health, which secured $3.03M in May, 2026.

Who are the top competitors of Caldera Therapeutics?

Caldera Therapeutics' top competitors include Quell, Samsung Bioepis and Enveda. Among them, MRM Health secured the most recent funding round in May, 2026.

Caldera Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of a bispecific antibody for inflammatory and immunologic diseases. The company is focused on developing CLD-423, a clinical-stage bispecific antibody, for inflammatory bowel disease. CLD-423 targets the IL-23p19 and TL1A pathways. A Phase 1 healthy volunteer trial of CLD-423 is ongoing.

Website: www.calderatx.com/
Email ID: *****@calderatx.com

Key Metrics

Location

San Francisco, United States

Stage

Series A

Total Funding

$112M in 2 rounds

Latest Funding Round

Series A, Jan 08, 2026, $*****

Investors

Omega Funds & 4 more

Ranked

24^th among 58 active competitors

Similar Companies

Quell & 52 more

View Caldera Therapeutics' full profile

Caldera Therapeutics has raised a total funding of $112M over 2 rounds. Its first funding round was on Apr 2025. Its latest funding round was a Series A round on Jan 08, 2026 for $*****. 3 investors participated in its latest round. Caldera Therapeutics has 5 institutional investors.

Here is the list of recent funding rounds of Caldera Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 08, 2026	4585309	Series A	4854136	1932758	8611275	2821658
Apr 2025	7813486	Series A	2768633	3645435	5819688	Atlas Venture & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Caldera Therapeutics's funding rounds and investors

The founders of Caldera Therapeutics is Zhong Liu.

Here are the details of Caldera Therapeutics' key team members:

Zhong Liu: Co-Founder & Chief Technology Officer of Caldera Therapeutics.
Contact Info: 1 email address

View details of Caldera Therapeutics's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Caldera Therapeutics include Quell, Samsung Bioepis and Enveda. Here is the list of Top 10 competitors of Caldera Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Quell 2019, London (United Kingdom), Series B	Developer of engineered regulatory T cell therapies for immune diseases	$344M	Syncona, Fidelity Investments & 17 others	64/100
2nd	Samsung Bioepis 2012, Incheon (South Korea), Acquired	Developer of biosimilar drugs for the treatment of multiple diseases	-	Biogen, Samsung BioLogics	64/100
3rd	Enveda 2019, Boulder (United States), Series D	AI-based platform to decipher the chemistry of nature and develop new medicines	$517M	Premji Invest, Kinnevik & 29 others	63/100
4th	Kanvas Biosciences 2021, Ithaca (United States), Series A	Provider of imaging solutions for microbial research and infectious diseases	$77.5M	DCVC, Uncommon Denominator & 10 others	63/100
5th	Accropeutics 2017, Suzhou (China), Series C	Developer of drugs for inflammation, autoimmune diseases, and cancer	$62M	Orbimed, Shenzhen Capital Group & 7 others	58/100
6th	MRM Health 2020, Ghent (Belgium), Series B	Developer of optimized consortia therapeutics targeting inflammatory, CNS, and metabolic diseases	$79.2M	DuPont, Ackermans & van Haaren & 11 others	58/100
7th	OMass Therapeutics 2016, Oxford (United Kingdom), Series B	Developer of therapeutics for immunological and orphan diseases	$166M	Google Ventures, Northpond Ventures & 6 others	57/100
8th	Enterome 2008, Paris (France), Series E	Developer of immunomodulatory drugs targeting cancer and immune diseases	$130M	Seventure Partners, Lundbeck Foundation & 10 others	57/100
9th	Protagonist Therapeutics 2001, Milpitas (United States), Public	Developer of oral peptide therapeutics for gastrointestinal diseases	$67M	Lilly Ventures, Canaan & 12 others	56/100
10th	Athos Therapeutics 2019, Torrance (United States), Series A	Developer of AI-based therapeutics for treating autoimmune diseases	$38.3M	-	56/100
24th	Caldera Therapeutics San Francisco (United States), Series A	Developer of a bispecific antibody for inflammatory and immunologic diseases	$112M	Janus Henderson Investors, VenBio & 3 others	46/100